148 related articles for article (PubMed ID: 35469834)
21. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
22. Oral liposomes encapsulating ginsenoside compound K for rheumatoid arthritis therapy.
Li Z; Han S; Cui G; Xue B; Li J; Man Y; Zhang H; Teng L
Int J Pharm; 2023 Aug; 643():123247. PubMed ID: 37467813
[TBL] [Abstract][Full Text] [Related]
23. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.
Wei W; Huang S; Ling Q; Mao S; Qian Y; Ye W; Li F; Pan J; Lin X; Huang J; Huang X; Zhai Y; Sun J; Jin J
J Transl Med; 2022 Jul; 20(1):299. PubMed ID: 35794605
[TBL] [Abstract][Full Text] [Related]
24. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
Mayer LD; Tardi P; Louie AC
Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
[TBL] [Abstract][Full Text] [Related]
25. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
26. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
Lin TY; Zhu Y; Li Y; Zhang H; Ma AH; Long Q; Keck J; Lam KS; Pan CX; Jonas BA
Nanomedicine; 2019 Aug; 20():102004. PubMed ID: 31055076
[TBL] [Abstract][Full Text] [Related]
27. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.
Fassas A; Anagnostopoulos A
Leuk Lymphoma; 2005 Jun; 46(6):795-802. PubMed ID: 16019523
[TBL] [Abstract][Full Text] [Related]
28. Cardiolipin for Enhanced Cellular Uptake and Cytotoxicity of Thermosensitive Liposome-Encapsulated Daunorubicin toward Breast Cancer Cell Lines.
Alrbyawi H; Boddu SHS; Poudel I; Annaji M; Mita N; Arnold RD; Tiwari AK; Babu RJ
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233061
[TBL] [Abstract][Full Text] [Related]
29. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
Ni S; Stephenson SM; Lee RJ
Anticancer Res; 2002; 22(4):2131-5. PubMed ID: 12174894
[TBL] [Abstract][Full Text] [Related]
30. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
31. Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
Zhou H; Xu RZ; Gu Y; Shi PF; Qian S
Leuk Lymphoma; 2020 May; 61(5):1084-1096. PubMed ID: 29334312
[TBL] [Abstract][Full Text] [Related]
32. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
Tang J; Liu Y; Chen J; Xue H; Pan C; Gu L
Int J Hematol; 2011 May; 93(5):610-617. PubMed ID: 21509439
[TBL] [Abstract][Full Text] [Related]
33. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies.
Kantarjian H; O'Brien S; Jabbour E; Barnes G; Pathak A; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):13-21. PubMed ID: 25458084
[TBL] [Abstract][Full Text] [Related]
35. Folate-Modified Liposomes Loaded with Telmisartan Enhance Anti-Atherosclerotic Potency for Advanced Atherosclerosis in ApoE
Fang D; Jin Q; Jin Z; Wang F; Huang L; Yang Y; He Z; Liu Y; Jiang C; Wu J; Song X
J Biomed Nanotechnol; 2019 Jan; 15(1):42-61. PubMed ID: 30480514
[TBL] [Abstract][Full Text] [Related]
36. Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment.
Guo D; Xu P; Chen D; Wang L; Zhu Y; Zuo Y; Chen B
Int J Nanomedicine; 2020; 15():521-536. PubMed ID: 32021192
[TBL] [Abstract][Full Text] [Related]
37. Preparation and in vivo safety evaluations of antileukemic homoharringtonine-loaded PEGylated liposomes.
Liu D; Xing J; Xiong F; Yang F; Gu N
Drug Dev Ind Pharm; 2017 Apr; 43(4):652-660. PubMed ID: 28005445
[TBL] [Abstract][Full Text] [Related]
38. A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin.
Cheng J; Wang J; Chen B; Xia G; Cai X; Liu R; Ren Y; Bao W; Wang X
Int J Nanomedicine; 2011; 6():2123-31. PubMed ID: 22114476
[TBL] [Abstract][Full Text] [Related]
39. pH-sensitive folic acid and dNP2 peptide dual-modified liposome for enhanced targeted chemotherapy of glioma.
Li M; Shi K; Tang X; Wei J; Cun X; Chen X; Yu Q; Zhang Z; He Q
Eur J Pharm Sci; 2018 Nov; 124():240-248. PubMed ID: 30071282
[TBL] [Abstract][Full Text] [Related]
40. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
Chen X; Tang Y; Chen J; Chen R; Gu L; Xue H; Pan C; Tang J; Shen S
Front Med; 2019 Jun; 13(3):378-387. PubMed ID: 30635781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
